Human Papilloma Virus-Associated Cervical Cancer and Health Disparities

Cervical cancer develops through persistent infection with high-risk human papilloma virus (hrHPV) and is a leading cause of death among women worldwide and in the United States. Periodic surveillance through hrHPV and Pap smear-based testing has remarkably reduced cervical cancer incidence worldwide and in the USA. However, considerable discordance in the occurrence and outcome of cervical cancer in various populations exists. Lack of adequate health insurance appears to act as a major socioeconomic burden for obtaining cervical cancer preventive screening in a timely manner, which results in disparate cervical cancer incidence. On the other hand, cervical cancer is aggressive and often detected in advanced stages, including African American and Hispanic/Latina women. In this context, our knowledge of the underlying molecular mechanism and genetic basis behind the disparate cervical cancer outcome is limited. In this review, we shed light on our current understanding and knowledge of racially disparate outcomes in cervical cancer.

[1]  Weiqin Chang,et al.  The Progress of Methylation Regulation in Gene Expression of Cervical Cancer , 2018, International journal of genomics.

[2]  Jing Zhang,et al.  Long Non-coding RNA DLEU1 Promotes Proliferation and Invasion by Interacting With miR-381 and Enhancing HOXA13 Expression in Cervical Cancer , 2018, Front. Genet..

[3]  T. Perren,et al.  Improved Survival with Bevacizumab in Advanced Cervical Cancer. , 2017, The New England journal of medicine.

[4]  M. Schwartz,et al.  Role of HPV genotyping in risk assessment among cytology diagnosis categories: analysis of 4562 cases with cytology–HPV cotesting and follow-up biopsies , 2019, International Journal of Gynecologic Cancer.

[5]  J. Berkhof,et al.  Combined CADM1/MAL Methylation and Cytology Testing for Colposcopy Triage of High-Risk HPV-Positive Women , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[6]  Too many women are dying from cervix cancer: Problems and solutions. , 2018, Gynecologic oncology.

[7]  M. Schiffman,et al.  Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer , 2017, International journal of cancer.

[8]  J. Tabernero,et al.  New clinical trial designs in the era of precision medicine , 2019, Molecular oncology.

[9]  K. Thangaraj,et al.  Mitochondrial DNA variation analysis in cervical cancer. , 2014, Mitochondrion.

[10]  C. Meijer,et al.  Genome-wide DNA Methylation Profiling Reveals Methylation Markers Associated with 3q Gain for Detection of Cervical Precancer and Cancer , 2017, Clinical Cancer Research.

[11]  S. Dasgupta Mitochondrion: I am more than a fuel server. , 2019, Annals of translational medicine.

[12]  J. Xiong,et al.  MicroRNA-140-5p targets insulin like growth factor 2 mRNA binding protein 1 (IGF2BP1) to suppress cervical cancer growth and metastasis , 2016, Oncotarget.

[13]  J. Berkhof,et al.  Performance of CADM1/MAL-methylation analysis for monitoring of women treated for high-grade CIN. , 2016, Gynecologic oncology.

[14]  B. Dyer,et al.  Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  U. Macleod,et al.  Interventions to improve the uptake of cervical cancer screening among lower socioeconomic groups: A systematic review. , 2017, Preventive medicine.

[16]  Jian Wang,et al.  BAP31, a newly defined cancer/testis antigen, regulates proliferation, migration, and invasion to promote cervical cancer progression , 2018, Cell Death & Disease.

[17]  M. Jit,et al.  A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls , 2013, PloS one.

[18]  Xu-dong Yang,et al.  Association of MBL2 exon1 polymorphisms with high-risk human papillomavirus infection and cervical cancers: a meta-analysis , 2016, Archives of Gynecology and Obstetrics.

[19]  C. Iacobuzio-Donahue,et al.  Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers , 2011, Oncotarget.

[20]  Oluwadamilola O Olaku,et al.  Cancer in the Medically Underserved Population. , 2017, Primary care.

[21]  C. Cready,et al.  Race and Ethnic Disparities in Cervical Cancer Screening in a Safety-Net System , 2005, Maternal and Child Health Journal.

[22]  S. Meghani,et al.  Health Care‐Related Correlates of Cervical Cancer Screening among Sexual Minority Women: An Integrative Review , 2018, Journal of midwifery & women's health.

[23]  Diane Solomon,et al.  Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting. , 2013, The New England journal of medicine.

[24]  L. Corey,et al.  Personalized Medicine in Gynecologic Cancer: Fact or Fiction? , 2019, Obstetrics and gynecology clinics of North America.

[25]  D. Miller,et al.  Telomeric associations and consistent growth factor overexpression detected in giant cell tumor of bone. , 1991, Cancer genetics and cytogenetics.

[26]  Nathan L. Vanderford,et al.  A Social-Ecological Review of Cancer Disparities in Kentucky , 2018, Southern medical journal.

[27]  M. Hoque,et al.  Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. , 2008, Cancer research.

[28]  D. Harper,et al.  HPV vaccines - A review of the first decade. , 2017, Gynecologic oncology.

[29]  Qi Zhang,et al.  KLF5 promotes cervical cancer proliferation, migration and invasion in a manner partly dependent on TNFRSF11a expression , 2017, Scientific Reports.

[30]  K. Miyamoto,et al.  Aberrant DNA methylation of DLX4 and SIM1 is a predictive marker for disease progression of uterine cervical low‐grade squamous intraepithelial lesion , 2015, Diagnostic cytopathology.

[31]  W. Lam,et al.  Mitochondrial DNA mutations in respiratory complex‐I in never‐smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation , 2012, Journal of cellular physiology.

[32]  S. Feldman Making sense of the new cervical-cancer screening guidelines. , 2011, The New England journal of medicine.

[33]  M. Schiffman,et al.  A prospective study of risk‐based colposcopy demonstrates improved detection of cervical precancers , 2018, American journal of obstetrics and gynecology.

[34]  Arelis Moore de Peralta,et al.  Cues to Cervical Cancer Screening Among U.S. Hispanic Women , 2017, Hispanic health care international : the official journal of the National Association of Hispanic Nurses.

[35]  A. Botezatu,et al.  Mitochondrial DNA mutations in patients with HRHPV-related cervical lesions. , 2011, Roumanian archives of microbiology and immunology.

[36]  SaxenaAnshul,et al.  Disparities in Cervical Cancer Characteristics and Survival Between White Hispanics and White Non-Hispanic Women. , 2016 .

[37]  V. Tsu,et al.  Saving the World's Women from Cervical Cancer. , 2016, The New England journal of medicine.

[38]  S. Syrjänen,et al.  From HPV Infection to Lesion Progression: The Role of HLA Alleles and Host Immunity , 2019, Acta Cytologica.

[39]  Kate L. Hertweck,et al.  The Landscape of mtDNA Modifications in Cancer: A Tale of Two Cities , 2017, Front. Oncol..

[40]  L. Cory,et al.  ADXS-HPV: A therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen , 2014, Human vaccines & immunotherapeutics.

[41]  Mariska Bierkens,et al.  CADM1 and MAL promoter methylation levels in hrHPV‐positive cervical scrapes increase proportional to degree and duration of underlying cervical disease , 2013, International journal of cancer.

[42]  A. Warowicka,et al.  Alterations in mtDNA: a qualitative and quantitative study associated with cervical cancer development. , 2013, Gynecologic oncology.

[43]  C. Fang,et al.  Ethnic density and cancer: A review of the evidence , 2018, Cancer.

[44]  T. Caputo,et al.  Disparities in Gynecological Malignancies , 2016, Front. Oncol..

[45]  Michael W Sill,et al.  Improved survival with bevacizumab in advanced cervical cancer. , 2014, The New England journal of medicine.

[46]  S. Rhodes,et al.  Increasing Cervical Cancer Screening Among US Hispanics/Latinas: A Qualitative Systematic Review , 2014, Journal of Cancer Education.

[47]  Steven J. M. Jones,et al.  Integrated genomic and molecular characterization of cervical cancer , 2017, Nature.

[48]  J. Bolin,et al.  Cervical Cancer Screening Barriers and Risk Factor Knowledge Among Uninsured Women , 2017, Journal of Community Health.

[49]  S. Roychowdhury,et al.  Differential deletions of chromosome 3p are associated with the development of uterine cervical carcinoma in Indian patients , 2003, Molecular pathology : MP.

[50]  Elizabeth R. Unger,et al.  Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices , 2015, MMWR. Morbidity and mortality weekly report.

[51]  J. Kahn,et al.  HPV vaccination for the prevention of cervical intraepithelial neoplasia. , 2009, The New England journal of medicine.

[52]  Ying Xia,et al.  microRNA-328 inhibits cervical cancer cell proliferation and tumorigenesis by targeting TCF7L2. , 2016, Biochemical and biophysical research communications.

[53]  HMGA1 exacerbates tumor growth through regulating the cell cycle and accelerates migration/invasion via targeting miR-221/222 in cervical cancer , 2018, Cell Death & Disease.

[54]  Suping Han,et al.  Cytochrome P450 1A1 gene polymorphisms and cervical cancer risk , 2018, Medicine.

[55]  A. Fader Surgery in Cervical Cancer. , 2018, The New England journal of medicine.

[56]  T. Stokke,et al.  Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix , 2004, International journal of cancer.

[57]  Jing Cai,et al.  miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-βRI signaling pathway , 2018, Cell Death & Disease.

[58]  P. Rao,et al.  Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma , 2004, BMC Cancer.

[59]  S. Yao,et al.  Down-regulation of HPGD by miR-146b-3p promotes cervical cancer cell proliferation, migration and anchorage-independent growth through activation of STAT3 and AKT pathways , 2018, Cell Death & Disease.

[60]  M. Mansukhani,et al.  Genetic analysis identifies putative tumor suppressor sites at 2q35–q36.1 and 2q36.3–q37.1 involved in cervical cancer progression , 2003, Oncogene.

[61]  E. Ratner,et al.  Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers , 2018, Front. Oncol..

[62]  Tiara Bunga Mayang Permata,et al.  Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy , 2018, Oncotarget.

[63]  A. Umar,et al.  Cancer prevention and screening: the next step in the era of precision medicine , 2019, npj Precision Oncology.

[64]  Juan Li,et al.  RETRACTED ARTICLE: Fibulin-3 knockdown inhibits cervical cancer cell growth and metastasis in vitro and in vivo , 2018, Scientific Reports.

[65]  A. Giuliano,et al.  Prevention of Invasive Cervical Cancer in the United States: Past, Present, and Future , 2012, Cancer Epidemiology, Biomarkers and Prevention.

[66]  C. Iavazzo,et al.  Management of ASCUS findings in Papanicolaou smears. A retrospective study. , 2012, European journal of gynaecological oncology.

[67]  L. Chinula,et al.  Making HPV vaccination available to girls everywhere , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[68]  J. Roa,et al.  Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix , 2012, Clinical Epigenetics.

[69]  M. Einstein,et al.  Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. , 2010, Gynecologic oncology.

[70]  Henry C Kitchener,et al.  Human papillomavirus and cervical cancer , 2013, The Lancet.

[71]  S. Hur,et al.  DNA methylation in human papillomavirus-infected cervical cells is elevated in high-grade squamous intraepithelial lesions and cancer , 2015, Journal of gynecologic oncology.

[72]  A. Services,et al.  Integrated genomic and molecular characterization of cervical cancer. , 2017 .

[73]  C. Desmarais,et al.  Intramuscular Therapeutic Vaccination Targeting HPV16 Induces T Cell Responses That Localize in Mucosal Lesions , 2014, Science Translational Medicine.

[74]  N. Horowitz,et al.  Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival , 2018, PloS one.

[75]  J. Conejo-Garcia,et al.  PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. , 2018, Integrative cancer science and therapeutics.

[76]  M. Marino,et al.  Role of Race/Ethnicity, Language, and Insurance in Use of Cervical Cancer Prevention Services Among Low-Income Hispanic Women, 2009–2013 , 2018, Preventing chronic disease.

[77]  Johannes Berkhof,et al.  Combined CADM1 and MAL promoter methylation analysis to detect (pre‐)malignant cervical lesions in high‐risk HPV‐positive women , 2011, International journal of cancer.

[78]  Hafiz M. R. Khan,et al.  Health disparities between Black Hispanic and Black non-Hispanic cervical cancer cases in the USA. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[79]  Y. Huang,et al.  MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 and p27Kip1 , 2014, British Journal of Cancer.

[80]  S. Murphy,et al.  Disparities in Cervical Cancer Incidence and Mortality: Can Epigenetics Contribute to Eliminating Disparities? , 2017, Advances in cancer research.

[81]  N. E. Thomford,et al.  Genetic Susceptibility for Cervical Cancer in African Populations: What Are the Host Genetic Drivers? , 2018, Omics : a journal of integrative biology.

[82]  S. Stokley,et al.  Ten Years of Human Papillomavirus Vaccination in the United States. , 2018, Academic pediatrics.

[83]  X. Yi,et al.  Comprehensive genomic variation profiling of cervical intraepithelial neoplasia and cervical cancer identifies potential targets for cervical cancer early warning , 2018, Journal of Medical Genetics.